LY2603618 + pemetrexed

LY2603618 + pemetrexed is a combination therapy that has been investigated in clinical trials for the treatment of non-small cell lung cancer (NSCLC). LY2603618 is a selective inhibitor of checkpoint kinase 1 (CHK1), a key regulator of the DNA damage checkpoint[1][2]. This combination was designed with the rationale that CHK1 inhibition may enhance the effects of antimetabolites like pemetrexed[1][2]. ## Mechanism of Action LY2603618 selectively inhibits CHK1 with an IC50 of 7nM (>1000x selectivity over CHK2)[5]. CHK1 plays a crucial role in regulating the DNA damage response. The combination of LY2603618 with pemetrexed was predicted to enhance the antitumor effects of pemetrexed[1]. Preclinical studies demonstrated that combination treatment of LY2603618 with pemetrexed arrested DNA synthesis following initiation of S-phase in cells[2]. Experiments with tumor-bearing mice showed a significant increase in growth inhibition of NCI-H2122 and NCI-H441 xenograft tumors when treated with the combination compared to either agent alone[2]. ## Clinical Development Multiple clinical trials have evaluated this combination: - A Phase I dose-escalation study examined the safety and tolerability of LY2603618 in combination with pemetrexed, determining that LY2603618 administered approximately 24 hours after pemetrexed showed acceptable safety and pharmacokinetic profiles[6]. - A Phase II trial assessed the overall response rate, safety, and pharmacokinetics of LY2603618 and pemetrexed in patients with NSCLC. In this study, patients received pemetrexed (500 mg/m²) on day 1 and LY2603618 (150 mg/m²) on day 2 every 21 days until disease progression[1]. - Another study evaluated LY2603618 in combination with pemetrexed and cisplatin, determining that the recommended Phase II dose of LY2603618 was 275 mg[2]. ## Efficacy and Safety In the Phase II evaluation of LY2603618 with pemetrexed in NSCLC patients, no patients experienced a complete response, while partial responses were observed in 5 patients (9.1%) and stable disease in 20 patients (36.4%)[1]. The median progression-free survival was 2.3 months[1]. The most frequently reported adverse events included fatigue, nausea, pyrexia, neutropenia, and vomiting[2]. The safety profile of LY2603618 in combination with pemetrexed was generally acceptable[1][6]. Pharmacokinetic studies showed that the systemic exposure of LY2603618 increased in a dose-dependent manner, and the pharmacokinetics of LY2603618 and pemetrexed were not altered when used in combination[1][2]. Despite the theoretical promise, the Phase II trial concluded that there was no significant clinical activity of LY2603618 and pemetrexed combination therapy in patients with advanced NSCLC, with results comparable to historical pemetrexed single-agent data[1].

Other names

rabusertib + pemetrexedLY2603618 + pemetrexed